静注阿奇霉素治疗呼吸系统感染的临床研究

Clinical study of intravenous azithromycin in the treatment of respiratory infection

目的 评价阿奇霉素静脉注射剂对呼吸系统感染的临床疗效及不良反应。方法 轻到中度呼吸系统感染患者44例 ,随机分为 2组 ,一组使用阿奇霉素治疗 5天 ,另一组使用红霉素治疗 7～ 14天 ,对临床疗效及不良反应进行评价 ,在治疗前、治疗后第 4天以及治疗结束后 1天进行细菌学评价。结果 44例患者入选 ,41例完成观察。阿奇霉素组治疗有效率为95 .2 3% ,而红霉素组为 85 % (P >0 .0 5 ) ;二组中分别检出 16株细菌 ,并分别有 15株被清除 (93.75 % ) ;阿奇霉素组药物不良反应的发生率为 14.3% ,红霉素组为 17.4% (P >0 .0 5 )。结论 静脉注射阿奇霉素 5天与使用红霉素 7～ 14天的临床疗效相当 ;阿奇霉素的副作用发生率较低 ,主要为一过性 AL

Objective To evaluate curative effect and safety of intravenous azithromycin for the treatment of respiratory infection Methods Controlled trial in which patient with mild to moderate respiratory infections were randomized to receive either azithromycin for 5 days or erythromycin for 7~14 days Patients were evaluated for clinical outcomes and adverse events Microbiology was done at baseline and day 4,after 1 days of treatment completed for bacteria Results Of 44 patient enrolled,41were evaluable Clinincal success was 95 23% in the azithromycin group and 85% in the erythromycin group(P<0 05) In two groups,16 bacteria were identified and 15(93 75%)were eradication,respectively Treatment-related adverse events occurred in 14 3% of the azithromycin group and 17 4% in the erythromycin group(P<0 05) Conclusion Intravenous azithromycin used once daily for 5 days produced a satisfactory therapeutic outcome similar to erythromycin 7~14 days for treatment of mild to moderate respiratory infections Azithromycin had fewer side effects,which is mainly ALT elevated